XOMA (NASDAQ:XOMA) Rating Reiterated by HC Wainwright

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They currently have a $117.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 297.42% from the company’s previous close.

Separately, StockNews.com upgraded shares of XOMA from a “sell” rating to a “hold” rating in a research report on Wednesday, August 14th.

XOMA Stock Performance

XOMA stock traded down $0.41 during trading on Friday, hitting $29.44. 17,999 shares of the company traded hands, compared to its average volume of 20,648. XOMA has a 1 year low of $13.48 and a 1 year high of $30.36. The company has a market cap of $344.45 million, a PE ratio of -7.51 and a beta of 0.93. The stock’s 50-day simple moving average is $27.49 and its 200 day simple moving average is $25.85. The company has a debt-to-equity ratio of 1.15, a current ratio of 8.71 and a quick ratio of 8.71.

XOMA (NASDAQ:XOMA) last posted its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). XOMA had a negative net margin of 128.59% and a negative return on equity of 24.50%. The firm had revenue of $11.09 million during the quarter, compared to analyst estimates of $8.37 million. On average, equities analysts expect that XOMA will post -1.42 earnings per share for the current fiscal year.

Hedge Funds Weigh In On XOMA

Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its stake in shares of XOMA by 55.6% in the 1st quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 1,266 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of XOMA during the 1st quarter valued at about $212,000. Bank of New York Mellon Corp grew its holdings in shares of XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares during the period. Finally, Rhumbline Advisers increased its position in XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after purchasing an additional 1,334 shares during the last quarter. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.